Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)

SEK 1.33

(-4.68%)

Total Debt Summary of Scandinavian ChemoTech AB (publ)

  • Scandinavian ChemoTech AB (publ)'s latest annual total debt in 2023 was - SEK , down 0.0% from previous year.
  • Scandinavian ChemoTech AB (publ)'s latest quarterly total debt in 2024 Q1 was - SEK , down 0.0% from previous quarter.
  • Scandinavian ChemoTech AB (publ) reported annual total debt of - SEK in 2022, down -100.0% from previous year.
  • Scandinavian ChemoTech AB (publ) reported annual total debt of 53 Thousand SEK in 2021, down -98.05% from previous year.
  • Scandinavian ChemoTech AB (publ) reported quarterly total debt of - SEK for 2024 Q1, down 0.0% from previous quarter.
  • Scandinavian ChemoTech AB (publ) reported quarterly total debt of - SEK for 2023 Q2, down 0.0% from previous quarter.

Annual Total Debt Chart of Scandinavian ChemoTech AB (publ) (2023 - 2013)

Historical Annual Total Debt of Scandinavian ChemoTech AB (publ) (2023 - 2013)

Year Total Debt Total Debt Growth
2023 - SEK 0.0%
2022 - SEK -100.0%
2021 53 Thousand SEK -98.05%
2020 2.71 Million SEK -48.74%
2019 5.28 Million SEK 1083.22%
2018 447 Thousand SEK -26.15%
2017 605.26 Thousand SEK -11.54%
2016 684.21 Thousand SEK -8.77%
2015 750 Thousand SEK 0.0%
2014 - SEK 0.0%
2013 - SEK 0.0%

Peer Total Debt Comparison of Scandinavian ChemoTech AB (publ)

Name Total Debt Total Debt Difference
Calliditas Therapeutics AB (publ) 979.13 Million SEK 100.0%
AcouSort AB (publ) - SEK NaN%
Active Biotech AB (publ) 3 Million SEK 100.0%
Alzinova AB (publ) 800 Thousand SEK 100.0%
Amniotics AB (publ) 2.58 Million SEK 100.0%
Asarina Pharma AB (publ) 1 Million SEK 100.0%
BioArctic AB (publ) 4.97 Million SEK 100.0%
Camurus AB (publ) 24.5 Million SEK 100.0%
Cantargia AB (publ) - SEK NaN%
Elicera Therapeutics AB (publ) - SEK NaN%
Genovis AB (publ.) 79.32 Million SEK 100.0%
Guard Therapeutics International AB (publ) - SEK NaN%
Mendus AB (publ) 24.48 Million SEK 100.0%
Kancera AB (publ) - SEK NaN%
Karolinska Development AB (publ) 3.07 Million SEK 100.0%
LIDDS AB (publ) - SEK NaN%
Lipum AB (publ) 1.76 Million SEK 100.0%
Lipigon Pharmaceuticals AB (publ) - SEK NaN%
Magle Chemoswed Holding AB (publ) 60.3 Million SEK 100.0%
Modus Therapeutics Holding AB (publ) - SEK NaN%
NextCell Pharma AB - SEK NaN%
OncoZenge AB (publ) - SEK NaN%
Saniona AB (publ) 71.4 Million SEK 100.0%
Simris Alg AB (publ) 90.74 Million SEK 100.0%
Vicore Pharma Holding AB (publ) - SEK NaN%
Xbrane Biopharma AB (publ) 231.47 Million SEK 100.0%
Xintela AB (publ) - SEK NaN%
Ziccum AB (publ) 857 Thousand SEK 100.0%
Isofol Medical AB (publ) - SEK NaN%
Xspray Pharma AB (publ) 36.8 Million SEK 100.0%
CombiGene AB (publ) - SEK NaN%
Diamyd Medical AB (publ) 30.67 Million SEK 100.0%
Intervacc AB (publ) 181 Thousand SEK 100.0%
Alligator Bioscience AB (publ) 16.09 Million SEK 100.0%
Sprint Bioscience AB (publ) - SEK NaN%
QuiaPEG Pharmaceuticals Holding AB (publ) 20.61 Million SEK 100.0%
Corline Biomedical AB - SEK NaN%
IRLAB Therapeutics AB (publ) 27.56 Million SEK 100.0%
Bio-Works Technologies AB (publ) - SEK NaN%
Aptahem AB (publ) 5 Million SEK 100.0%
Infant Bacterial Therapeutics AB (publ) - SEK NaN%
Fluicell AB (publ) - SEK NaN%
Biovica International AB (publ) 7.82 Million SEK 100.0%
Spago Nanomedical AB (publ) - SEK NaN%
Abliva AB (publ) 424 Thousand SEK 100.0%
Egetis Therapeutics AB (publ) 108.6 Million SEK 100.0%
2cureX AB (publ) - SEK NaN%
I-Tech AB - SEK NaN%
Hansa Biopharma AB (publ) 866.76 Million SEK 100.0%
Cyxone AB (publ) 858 Thousand SEK 100.0%
ExpreS2ion Biotech Holding AB (publ) 1.71 Million SEK 100.0%
Biosergen AB - SEK NaN%
Nanologica AB (publ) 666 Thousand SEK 100.0%
SynAct Pharma AB 637 Thousand SEK 100.0%
Annexin Pharmaceuticals AB (publ) - SEK NaN%
BioInvent International AB (publ) 23.24 Million SEK 100.0%
Stayble Therapeutics AB (publ) 850 Thousand SEK 100.0%
Oncopeptides AB (publ) 106.48 Million SEK 100.0%
Pila Pharma AB (publ) 773.08 Thousand SEK 100.0%
Ascelia Pharma AB (publ) 1.06 Million SEK 100.0%
Diagonal Bio AB (publ) - SEK NaN%